Expand all sections

Pembrolizumab

Keytruda

Extended indication KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung c
Therapeutic value Possible added value
Registration phase Registered

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information